193 related articles for article (PubMed ID: 35717220)
1. [New drug approval: Lisocabtagene maraleucel for patients with relapsed or refractory diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma or follicular lymphoma grade 3B after two or more lines of systemic treatment].
Chiche E; Loschi M
Bull Cancer; 2022 Sep; 109(9):879-880. PubMed ID: 35717220
[No Abstract] [Full Text] [Related]
2. [Lisocabtagene maraleucel CAR-T cells - second line treatment in patients with relapsed or refractory large B cell lymphoma].
Chanut M; Herbaux C
Bull Cancer; 2023 Oct; 110(10):986-988. PubMed ID: 37661551
[No Abstract] [Full Text] [Related]
3. Lisocabtagene maraleucel in the treatment of relapsed/refractory large B-cell lymphoma.
St-Pierre F; Gordon LI
Future Oncol; 2023 Jan; 19(1):19-28. PubMed ID: 36651471
[TBL] [Abstract][Full Text] [Related]
4. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
Abramson JS; Palomba ML; Gordon LI; Lunning MA; Wang M; Arnason J; Mehta A; Purev E; Maloney DG; Andreadis C; Sehgal A; Solomon SR; Ghosh N; Albertson TM; Garcia J; Kostic A; Mallaney M; Ogasawara K; Newhall K; Kim Y; Li D; Siddiqi T
Lancet; 2020 Sep; 396(10254):839-852. PubMed ID: 32888407
[TBL] [Abstract][Full Text] [Related]
5. Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study.
Sehgal A; Hoda D; Riedell PA; Ghosh N; Hamadani M; Hildebrandt GC; Godwin JE; Reagan PM; Wagner-Johnston N; Essell J; Nath R; Solomon SR; Champion R; Licitra E; Fanning S; Gupta N; Dubowy R; D'Andrea A; Wang L; Ogasawara K; Thorpe J; Gordon LI
Lancet Oncol; 2022 Aug; 23(8):1066-1077. PubMed ID: 35839786
[TBL] [Abstract][Full Text] [Related]
6. [New drug approval : Loncastuximab tesirine in diffuse large B-cell lymphoma relapsed/refractory after two lines of treatment].
Tauveron-Jalenques U; Bay JO
Bull Cancer; 2023 May; 110(5):476-477. PubMed ID: 36949000
[No Abstract] [Full Text] [Related]
7. Glofitamab: First Approval.
Shirley M
Drugs; 2023 Jul; 83(10):935-941. PubMed ID: 37285013
[TBL] [Abstract][Full Text] [Related]
8. New and emerging therapies for the treatment of relapsed/refractory diffuse large B-cell lymphoma.
Moore DC; Peery MR; Tobon KA; Raheem F; Hwang GS; Alhennawi L; Hughes ME
J Oncol Pharm Pract; 2022 Dec; 28(8):1848-1858. PubMed ID: 35469489
[TBL] [Abstract][Full Text] [Related]
9. [New European approvals: Tisagenlecleucel and Axicabtagene ciloleucel CAR-T cells - Follicular lymphoma after at least two and three prior lines of therapy].
Cordeil S; Bachy E
Bull Cancer; 2022 Nov; 109(11):1106-1108. PubMed ID: 36088178
[No Abstract] [Full Text] [Related]
10. New Approval for Drug Treating Large B-Cell Lymphoma.
Aschenbrenner DS
Am J Nurs; 2022 Oct; 122(10):20-21. PubMed ID: 36136022
[TBL] [Abstract][Full Text] [Related]
11. [Epcoritamab - relapsed or refractory large diffuse B cells lymphoma after two or more lines of systemic therapy].
Bensaber H; Cacheux V
Bull Cancer; 2024 Jun; 111(6):544-545. PubMed ID: 38631985
[No Abstract] [Full Text] [Related]
12. Lisocabtagene maraleucel for relapsed or refractory large B-cell non-Hodgkin lymphoma.
Mohty R; Moreno Vanegas Y; Chavez JC; Kharfan-Dabaja MA
Expert Rev Anticancer Ther; 2023 Feb; 23(2):121-126. PubMed ID: 36662602
[TBL] [Abstract][Full Text] [Related]
13. Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma.
Keating GM
Drugs; 2010 Jul; 70(11):1445-76. PubMed ID: 20614951
[TBL] [Abstract][Full Text] [Related]
14. In brief: Lisocabtagene maraleucel (Breyanzi) for large B-cell lymphoma.
Med Lett Drugs Ther; 2023 Jun; 65(1679):e104-e105. PubMed ID: 37339093
[No Abstract] [Full Text] [Related]
15. Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma.
Chow VA; Shadman M; Gopal AK
Blood; 2018 Aug; 132(8):777-781. PubMed ID: 29914976
[TBL] [Abstract][Full Text] [Related]
16. Lisocabtagene maraleucel for treatment of relapsed and refractory primary mediastinal large B-cell lymphoma in an adolescent patient.
Lee D; Goyal A; Wang WL; Ananth S; Lau E; Binkley MS; Bharadwaj S; Dahiya S
EJHaem; 2024 Feb; 5(1):153-156. PubMed ID: 38406546
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of axicabtagene ciloleucel versus lisocabtagene maraleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the US.
Oluwole OO; Liu R; Diakite I; Feng C; Patel A; Nourhussein I; Snider JT; Locke FL
J Med Econ; 2022; 25(1):541-551. PubMed ID: 35443867
[TBL] [Abstract][Full Text] [Related]
18. Use of a real-world synthetic control arm for direct comparison of lisocabtagene maraleucel and conventional therapy in relapsed/refractory large B-cell lymphoma.
Van Le H; Van Naarden Braun K; Nowakowski GS; Sermer D; Radford J; Townsend W; Ghesquieres H; Menne T; Porpaczy E; Fox CP; Schusterbauer C; Liu FF; Yue L; De Benedetti M; Hasskarl J
Leuk Lymphoma; 2023 Mar; 64(3):573-585. PubMed ID: 36755418
[TBL] [Abstract][Full Text] [Related]
19. In Vivo Cellular Expansion of Lisocabtagene Maraleucel and Association With Efficacy and Safety in Relapsed/Refractory Large B-Cell Lymphoma.
Ogasawara K; Lymp J; Mack T; Dell'Aringa J; Huang CP; Smith J; Peiser L; Kostic A
Clin Pharmacol Ther; 2022 Jul; 112(1):81-89. PubMed ID: 35156195
[TBL] [Abstract][Full Text] [Related]
20. Postinfusion monitoring costs by site of care for patients with relapsed/refractory large B-cell lymphoma receiving third- or later-line treatment with lisocabtagene maraleucel in the TRANSCEND NHL 001 and OUTREACH trials.
Palomba ML; Jun MP; Lymp J; Nguyen A; McGarvey N; Gitlin M; Pelletier C; Keating SJ; Godwin J
Leuk Lymphoma; 2021 Sep; 62(9):2169-2176. PubMed ID: 34018458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]